{
  "ticker": "RAD",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971287",
  "id": "02971287",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250722",
  "time": "0830",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250722/pdf/06m0dp8wsbj0jp.pdf",
  "summary": "### Summary:  \n**Announcement Type:** Key Personnel Appointment (Scientific Advisory Board)  \n\n- **Material Information:**  \n  - **Appointment:** Dr. Oliver Sartor, a globally recognized expert in prostate cancer and radiopharmaceutical therapies, joins Radiopharm\u2019s Scientific Advisory Board.  \n  - **Relevance:** Strengthens clinical and scientific credibility for Radiopharm\u2019s oncology radiopharmaceutical pipeline (Phase 1/2 trials in lung, breast, and brain cancers).  \n\n*No material financial, trading, or capital markets impact identified.*",
  "usage": {
    "prompt_tokens": 1145,
    "completion_tokens": 115,
    "total_tokens": 1260,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-21T22:57:19.377332"
}